An overview of antimicrobial peptides and the latest advances in their development

Josep M Sierra*, Ester Fusté-b, Francesc Rabanalc, Teresa Vinuesaa and Miguel Viñasd-d

*Laboratory of Molecular Microbiology and Antimicrobials, Department of Pathology and Experimental Therapeutics, School of Medicine, University of Barcelona, Barcelona, Spain; bDept. Public Health, Mental Health and Perinatal Nursing. School of Nursing, University of Barcelona, Barcelona, Spain; cDepartment of Organic Chemistry, Faculty of Chemistry, University of Barcelona, Barcelona, Spain; dDepartment of Biomedicine, Cooperativa de Ensino Superior Politécnico e Universitário, IINFACTS, Gandra, Portugal

ABSTRACT

Introduction: The recent dramatic increase in the incidence of antimicrobial resistance has been recognized by organizations such as the United Nations and World Health Organization as well as the governments of the USA and several European countries. A relatively new weapon in the fight against severe infections caused by multi-drug resistant bacteria is antimicrobial peptides (AMPs). These include colistin, currently regarded as the last line of antimicrobial therapy against multi-drug resistant microorganisms.

Areas covered: Here, the authors provide an overview of the current research on AMPs. The focus is AMPs currently being developed for the treatment of recalcitrant bacterial infections, the synergies of AMPs and antibiotics, and the activity of AMPs against biofilm. This review also includes a brief introduction into the use of AMPs in infections caused by Mycobacterium, fungi, and parasites.

Expert opinion: In research into new antimicrobials, AMPs are gaining increasing attention. While many natural are and are produced by a wide variety of organisms, others are being newly designed and chemically synthesized in the laboratory to achieve novel antimicrobial agents. The same strategy to fight infections in nature is thus being effectively exploited to safeguard human and animal health.

1. Introduction

Since the introduction of sulfonamides and the discovery of penicillin in 1928, the arsenal of drugs to treat infections has greatly expanded [1]. In fact, antibiotics have become the most commonly prescribed drugs and have greatly contributed to reducing mortality and morbidity due to infectious diseases. The ‘golden age of antibacterials’ describes the period between the 1940s and 1960s, when the vast majority of antibiotics currently in use were discovered [2]. Unfortunately, the utility of these drugs has been seriously compromised by the subsequent emergence of resistant bacteria (Table 1). The mechanisms underlying resistance are both genetic and environmental. For example, bacteria can specifically limit or reduce the permeability of their cell envelope to a given antibiotic and thus become resistant. In the case of *Pseudomonas aeruginosa*, it can acquire resistance to imipenem by losing expression of the porin OprD, the transporter for this antibiotic, either by mutation or disruption of the respective gene [3]. Alternatively, the bacterium may acquire the ability to degrade the antimicrobial, such as by ß-lactamase production. This latter mechanism is of particular concern because the emergence of expanded spectrum ß-lactamases (ESBLs) has led to the emergence of new, nonresponsive bacterial clones [4]. Resistance can also arise by the loss of chemical affinity between an antimicrobial and its target, as has commonly occurred in the case of streptococci; this mechanism was also the main cause of penicillin resistance in meningococci [5,6]. The wide variety of efflux systems able to pump out antimicrobials from the bacterial cell is another worrisome mechanism of resistance because most of the pumps are highly unspecific [7]. It is also now appreciated that bacteria residing in biofilms have a much lower antimicrobial susceptibility than their planktonic or microcolonial counterparts [8].

The emergence of resistance is well illustrated by methicillin, discovered in 1959 and subsequently introduced to treat penicillin-resistant *Staphylococcus aureus*. However, 2 years later, methicillin-resistant phenotypes strains were isolated, first in the United Kingdom and then in Japan, Australia, and elsewhere [9]. Similarly, the aminoglycoside streptomycin, which inhibits bacterial protein synthesis was introduced for the treatment of tuberculosis, but the emergence of rRNA mutations conferring streptomycin-resistance to *Mycobacterium tuberculosis* strains was soon reported [10].

The story has been the same for nearly every antibiotic, with the most recent example being lipopeptides, introduced at the beginning of this century. Strains resistant to at least one of them (daptomycin) are already known [11].

1.1. Antimicrobial resistance today

The US Center for Disease Control and Prevention (CDC) reported in 2013 that in two million people in the USA had suffered an infection caused by a resistant pathogen, and at...
Article highlights

- Antimicrobial peptides, potentially, offer advantages to become useful antimicrobials as they are less prone to generate microbial resistance.
- There are circa 20 new antimicrobial peptides in different stages of development.
- Natural antimicrobial peptides could be a starting point for the research on antimicrobial peptides.
- Due to the main mechanism of action antimicrobial peptides could be a useful hope when used in combination with classical antibiotics.
- Peptides with anti-mycobacterial, anti-fungal and anti-parasitic activities constitute also a promising family of compounds.

This box summarizes key points contained in the article.

Table 1. Temporal relationship between the antibiotic introduction in clinics and time of resistance development.

| Antibiotic deployment           | Years   | Antibiotic resistance observed |
|---------------------------------|---------|---------------------------------|
| Sulfonamides                    | Before 1935 |                                 |
| B-lactams (penicillin)          | 1936–1940 | Sulfonamides                    |
| Streptomycin                    | 1941–1945 | B-lactams (penicillin)          |
| Chloramphenicol                 | 1946–1950 | Tetracyclines                   |
| Tetracyclines Colistin          | 1951–1955 | Macrolides (erythromycin)       |
| Glycopeptides (vancomycin)      | 1956–1960 | Glycopeptides (vancomycin)      |
| Cephalosporins                  | 1961–1965 | Cephalosporins                  |
| Quinolones (nalidixic acid)     | 1966–1970 | Quinolones (nalidixic acid)     |
|                                 | 1971–1975 |                                 |
|                                 | 1976–1980 |                                 |
|                                 | 1981–1985 |                                 |
|                                 | 1986–1990 |                                 |
|                                 | 1991–1995 |                                 |
| Oxazolidinones (linezolid)      | 1996–2000 | Oxazolidinones (linezolid)      |
|                                 | 2001–2005 |                                 |
|                                 | 2006–2010 |                                 |
| ‘New antimicrobial peptides’    | 2011–beyond |                                 |

At least 23,000 of these individuals had died due to the infection. By about 2050, it is predicted that 10,000,000 deaths will be attributable to multiresistant bacteria [12]. The Infectious Disease Society of America (IDSA) highlighted Enterococcus faecium, S. aureus, Klebsiella pneumoniae, Acinetobacter baumannii, P. aeruginosa, and Enterobacter (ESKAPE) as species capable of ‘escaping’ the antibacterial action of antibiotics, including by the above-mentioned mechanisms. These species constitute a new paradigm in virulence, transmission, and antimicrobial resistance [13]. In 2014, the European Center for Disease Control published a report on antimicrobial resistance in Europe [14] that also focused on the ESKAPE pathogens. Increased levels of resistance, especially in southern European countries, were reported.

The development and spread of antibiotic-resistant bacteria are, at least in part, the result of the use, misuse, and abuse of antimicrobial agents in human and veterinary medicine as well as the food industry. In fact more than half of the antibiotics prescribed are not needed or are incorrectly used. Particularly troublesome is the widespread use of antibiotics (in many cases illegally) in livestock to promote animal growth and in aquaculture to prevent the contamination of fish stocks. Antibiotics are also prescribed indiscriminately in both humans and household pets. They have also been used as additives in cleaning products [15].

1.2. Antimicrobial peptides

Antimicrobial peptides both natural and synthetic are one of the main options to overcome resistance. Moreover, some peptides, particularly those that are similar to animal defense antimicrobial peptides (AMPs), have immunomodulatory activity [16].

With the current dilemma of widespread resistance, including extremely resistant organisms, but a lack of availability of new antimicrobial agents, attempts are being made to ‘revive’ older antimicrobials to treat serious infections. This is the case of colistin (polymyxin E), a natural AMP whose use was abandoned due its toxicity [17]. However, colistin is the last option to treat infections caused by multidrug resistant bacteria, including those caused by P. aeruginosa and/or A. baumannii. Instead, new AMPs are in the drug discovery and development pipeline.

2. Mechanisms of AMP action and resistance

2.1. Mechanism of action

Although membrane permeabilization is the main mechanism of action of AMPs against pathogens, additional mechanisms have been described, including membrane destabilization, inhibition of macromolecular synthesis, intracellular translocation of the peptide, and inhibition of DNA/RNA/protein synthesis [18]. The application of ‘omics’ to the study of resistance mechanisms has enabled explorations of transcript profiles and the role of individual genes in response to AMP challenge. For example, the AMPs pleurocidin, magainin, D-LAK120-AP13, and buforin II induce changes in alanine, aspartate, and glutamate metabolism and in the expression of gltX, dapA, and metB, encoding, respectively, glutamyl-tRNA synthetase, dihydropicolinate synthase, and cystathionine gamma-synthase. Several genes are upregulated in response to all four AMPs. Among them is yijB, which encodes a 157-amin acid, conserved, inner-membrane protein predicted to have four transmembrane helices but with unknown function. An integrated systems biology approach identified at least 1342 genes that are differentially expressed in response to the four AMPs. In Escherichia coli, this accounts for 30% of the bacterial genome and provides evidence of the wide variety of genes whose expression is altered by AMPs but also of the large number of functions that can be manipulated by the bacteria to acquire AMP resistance [19].

As polycationic peptides, AMPs interact electrostatically with negatively charged bacterial surface structures, including lipoteichoic acids (gram-positive bacteria), and they then gain access to the cytoplasmic membrane and interact with lipid bilayers, forming transmembrane pores and resulting in a remarkable dose-dependent weakening of the membrane [20]. In addition, the peptide/lipid ratio determines the nature
of AMP insertion into the membrane. At high peptide/lipid ratios, AMPs are perpendicularly oriented and form transmembrane pores whereas at low ratios the AMPs insert parallel to the bacterial membrane. However, the presence of cholesterol in the lipid membrane may alter the interaction between peptides and phospholipids such that there is reduced disruption of the bilayer and therefore less leakage [21].

Several models have been proposed to specifically explain how AMPs induce membrane permeabilization:

In the *barrel-stave model*, after their membrane attachment, when a threshold concentration of the AMP is reached, the peptide monomers aggregate to form transmembrane pores within the hydrophobic membrane core. This model is consistent with the mechanism of action of the channel-forming peptide antibiotic alamethicin.

In the *toroidal pore* model, the AMPs aggregate within the bilayer membranes such that the lipid monolayers to curve around the pore. The hydrophilic region of the AMP joins the bilayer membrane to form the outer part of the pore, while the hydrophobic part of forms its internal aspect. Consequently, the transmembrane pore is bordered by both the lipid head groups and the AMPs, allowing the water core to be lined. This model describes the mechanism of action of magainins (pexiganan, MSI-78) [22] and of LL-37 [23].

In the *carpet model*, AMPs are electrostatically attracted to the anionic phospholipids head groups and ‘carpet’ the surface of the membrane. Thus, high concentrations of AMPs exert detergent-like effects, via the formation of micelles and pores that disrupt the bacterial membrane. However, at a critical concentration, these AMPs form toroidal transient pores [18,20]. This model explains the mode of action of ovispirin, demaseptin natural analogs, cecropins, trichogin, and some magainins [24].

In the *aggregate model*, the electrostatic interactions between the phospholipid bilayer and the AMPs is followed by the formation of lipid–peptide complexes that induce the formation of nonspecifically oriented pores with heterogeneous shapes and sizes. This allows the AMPs to transiently cross the membrane such that their bacterial-killing effects are related to their interactions with intracellular targets, such as polyansions, DNA or RNA [18,24]. This is the case for the AMPs buforin II, pleurocidin, and dermaseptin, which inhibit DNA or mRNA synthesis.

However, besides these various forms of membrane permeabilization and intracellular killing, other mechanisms of cell death have been proposed for AMPs, including the inhibition of extracellular biopolymer synthesis and intracellular functions [20,25]. For example, indolcin and PR-39 interfere with protein synthesis and pyrrhocorin with correct protein folding. The lantibiotics nisin and mersacidin alter peptidoglycan synthesis whereas papillicin induces the production of oxygen free radicals, which damages both DNA and the cell membrane. Finally, other AMPs can inhibit the activity of a few anionic enzymes. As noted above, the wide variety of mechanisms, which lead to bacterial killing are consistent with the large number of genes whose expression is altered by AMP challenge [18].

### 2.2. Mechanisms of AMP resistance

As with the development of antibiotic resistance, bacteria can become resistant to AMPs. The frequency differs widely depending on the bacteria and the peptide [26]. Although the mechanisms of bacterial resistance to AMPs are not yet fully established, modification of the physical–chemical interaction between the AMP and the membrane to prevent permeabilization and the subsequent cellular osmotic imbalance is probably the first step in the development of bacterial resistance. The existence of mechanisms removing the peptides from their site of action has been reported as well as the emergence of new targets [27].

Some microorganisms are able to reduce their net negative charge, either by introducing positively charged groups, such as basic amino acids (*S. aureus*) or by changing the electronegativity of the cytoplasmic membrane, by diminishing the content of anionic phospholipids (e.g. *P. aeruginosa*).

Gram-positive pathogens such as *Streptococcus agalactiae* and *Listeria monocytogenes* neutralize the anionic charge of their wall by modifying teichoic acids with positively charged D-alanine residues. Other bacteria are surrounded by a capsule of polysaccharides that limits the interaction of AMPs with their targets. These capsule-forming bacteria are more resistant to AMPs than mutants that lack a capsule [20,26].

Among the strategies used by gram-negative bacteria to become resistant to AMPs is to decrease the anionic charge of lipid A (a main component of LPS) by acylation which reduces the fluidity of the outer membrane by increasing the hydrophobic interactions (e.g. in *E. coli*, *Salmonella* and *Haemophilus influenzae*). Alternatively, they can account for positive charges on choline, present on the membrane [20,24,27], or the structure of their outer membrane proteins. The latter is the case in *Yersinia enterocolitica*, an ability conferred by a 70-kb plasmid [20]. A further mechanism in gram-negative bacteria involves their resistance-nodulation-cell division efflux pumps (RND transporters) and ATP-binding cassette transporters, both of which can pump out AMPs to avoid their action. This mechanism has been well-studied in *E. coli*, in which the *yjABEF* operon has been related to bacterial uptake of the AMP microcin C, and in *Neisseria gonorrhoea*, in which the loss of the *MtrCDE* operon results in an enhanced susceptibility to AMPs [20,28]. Down-regulation of host AMP expression is also a typical survival strategy of gram-negative pathogens, such as the down-regulation of LL-37 and hBD, produced by the host, 1 by exotoxins of *Vibrio cholerae* and enterotoxigenic *E. coli* [28].

Finally, bacterial proteases usually have a broad spectrum of activity against peptides. The production of proteolytic enzymes by either gram-negative or gram-positive bacteria can result in the degradation of active AMP into inactive fragments and therefore AMP resistance. Thus, in gram-negative bacteria, mainly *Enterobacteriaceae*, the outer membrane protein OmpT of *E. coli* is able to degrade AMPs [28]. In gram-positive *S. aureus*, the same has been demonstrated for aureolysin [20].

### 3. Therapeutic application of antimicrobial peptides

AMPs hold several advantages as antimicrobials as they are less prone to generate microbial resistance than classical antibiotics. As discussed above, they act preferentially (but not exclusively) at the membrane level, may disrupt multiple biochemical processes in the pathogen, and may activate the immune system of the host. Nevertheless, there are still...
several pitfalls that need to be addressed regarding the development of their broader therapeutic application. These include the toxicity of AMPs, their pharmaceutical and pharmacological optimization (increased stability, reduced clearance rates), and the cost of their production. In fact, very few AMPs have reached the market. Of those that have, the majority are naturally occurring cyclic peptides that usually contain noncoded amino acids (β-amino acids, for instance).

4. The pipeline of antimicrobial peptides

4.1. Cyclic AMPs

Currently, there are roughly 20 AMPs in different development phases, from preclinical to clinical phase III trials (Table 2). A few are already clinically available, mainly but not only for topical applications [29].

The first AMPs introduced for clinical use were cyclic compounds. Among those already available for several decades are polymyxins (polymyxin B and colistin, polymyxin E), gramicidin, tyrothricin (tyrocidin is the main component), bacitracin, and daptomycin (Figure 1). Of these, the first AMP in clinical use in humans was tyrothricin. Discovered by René Dubos in 1939 as an active peptide produced by Bacillus brevis [1], it consists of a mixture of tyrocidine (~80%) and gramicidin (~20%). Tyrocidine itself is a complex mixture of cyclic peptides (tyrocidines A–D) containing 10 amino acids [30]. Due to the toxicity of tyrothricin, it is used only as a topical antimicrobial agent, typically in combination with anesthetics (benzocaine, lidocaine, and others), anti-inflammatory drugs (hydrocortisone), or other antibiotics (neomycin). For example, it is found in throat lozenges or sprays used for the treatment of throat irritation and infection [31].

Gramicidins were the first natural antibiotic discovered by means of a systematic, purposeful search for antibacterial compounds [1]. They are particularly effective against gram-positive bacteria and are mostly bacteriostatic, inhibiting bacterial growth, but at high concentrations they are also bactericidal. Gramicidin D is a heterogeneous mixture of three linear antibiotic pentadecapeptides: gramicidin A, B, and C. Like tyrothricin, they are produced by the soil bacterium B. brevis. Gramicidin S is a cyclic decapeptide that is also active against a few gram-negative bacteria, such as those of the Neisseria genus. Gramicidins cannot be administered systemically because of their pronounced hemolytic side effects. Instead, they are mainly used to treat infected surface wounds as well as ocular, nasal, and throat infections. Gramicidin is also a component of an ophthalmic solution containing the antibiotic neomycin and the AMP polymyxin B [32].

The polymyxins were discovered in 1947 and entered into clinical use in the 1960s, including as systemic drugs. They consist of a mixture of cyclic lipodecapeptides, mainly polymyxin B and colistin (polymyxin E). They are highly active against gram-negative bacteria, particularly most of the ESKAPE bacteria [33]. However, systemic use was abandoned beginning in the late 1970s because of reports of their toxicity (mostly nephrotoxicity but also neuromuscular blockage and neurotoxicity) and the availability of new, safer therapeutic options. Thus, today, polymyxins are mostly used for topical applications, in the treatment of eye infections and for selective decontamination of the digestive tract. However, due to the scarcity of new antibiotics against multidrug-resistant gram-negative bacteria, polymyxins have been rescued as a last resort treatment in patients with serious infections for whom no other therapeutic options exist. In addition, recent clinical studies found that polymyxins have a better therapeutic window than originally reported and therefore that better dosing strategies with fewer secondary effects could be developed. One such strategy is the application of nanotechnologies to produce nanoparticulated polymyxins [34,35]. In addition, a great deal of effort is currently being devoted to developing new polymyxin analogs with reduced toxicity [36–39].

Bacitracin is a cyclic peptide antibiotic commonly used in combination with polymyxin and neomycin (an aminoglycoside) as triple antibiotic ointment (Neosporin™) for the topical treatment of skin and eye infections. It is a complex mixture of related cyclopeptides produced by Bacillus subtilis var. Tracy. It was first isolated in 1945 from an infected wound that healed spontaneously in a pediatric patient with a complicated tibial fracture. Parenteral administration of bacitracin is highly restricted because it is nephrotoxic [32,40].

Daptomycin (Cubicin®) is also a cyclic lipodepsipeptide antibiotic that is anionic rather than cationic due to the presence of three aspartic acids and one methylglutamic acid not compensated by its single ornithine and kynurenine residues. It was approved by the Food and Drug Administration (FDA) in 2003 for the treatment of complicated skin and skin-structure infections (cSSSI) caused by susceptible isolates of gram-positive bacteria, particularly S. aureus (also methicillin-resistant strains) and including bloodstream infections by this bacterium (bacteremia) such as in patients with right-sided infective endocarditis [41].

Among the promising analogs of daptomycin is surotomycin, (also known as CB-315, CB-183315, MK4261), obtained from the parent compound by semisynthetic modification of its lipid moiety. Surotomycin is effective in Clostridium difficile, disrupting the bacterial membrane, and is currently in phase III clinical trials for the treatment of C. difficile-associated diarrhea. Due to its lack of activity against gram-negative anaerobes and facultative anaerobes, it minimally disturbs the normal gastrointestinal microbiota. In 2012, it was assigned Qualified Infectious Disease Product (QIDP) status in the USA, under the FDA’s GAIN Act, for the treatment of C. difficile-associated diarrhea. This means that priority review, fast-track status, and 5-year exclusivity after licensing are applicable [42].

POL7080 (murepavadin) is a cyclic protegrin I analog highly active and selective against protein LptD of P. aeruginosa. It has novel mechanism of action, targeting, outer membrane biogenesis. In preclinical studies, POL7080 showed high antimicrobial activity against a broad panel of clinical isolates, including multidrug resistant Pseudomonas strains. Excellent in vivo efficacy was reported in thigh, lung, and septicemia infection models [43]. Phase I clinical trial in healthy volunteers proved its clinical safety and tolerability, with no serious side effects. It is currently being tested in phase II clinical trials in patients suffering ventilator-associated bacterial pneumonia.
| Compound name | Origin | Mechanism of action | Indications | Development stage | Company (reference) |
|---------------|--------|---------------------|-------------|------------------|---------------------|
| Surotomycin  | Daptomycin | Membrane disruptor, depolarization | *C. difficile*-associated diarrhea | Phase III | Merck-Cubist (41) |
| POL7080      | Protegrin I | LptD binding | VAPP, bronchiectasis | Phase II | Polyphor (44, 45) |
| Pexiganan    | Magainin derivative | Disruption of bacterial cell membrane | Skin and skin structure infections | Evaluating development | Dipexium (46) |
| (L. occidentalis), MSI 80 | Pharmaceuticals | | | | |
| | | | | | |
| Omiganan (CLS001) | Indolicin | Cytoplasmatic membrane depolarization | Rosacea, Acne, atopic dermatitis, vulvar intraepithelial neoplasia | Phase III | Cutanea Life Sciences (48) |
| SGX 942      | Synthetic | Innate defense regulator | Oral mucositis in head and neck cancer | Phase II | Soligenix (49) |
| LTX-109      | Synthetic peptidomimetic | Membrane disruptor (cell lysis) | Diabetic foot and skin infections impetigo | Phase I/II | Cellceutix (51) |
| Brilacidin   | Synthetic defensin arylamide peptidomimetic | Bacterial cell membrane disruptor | ABSSSI Infections | Phase III | LTX Biopharma (51) |
| C16G2        | Hybrid (G2 + S. mutans region) | Membrane disruptor | Oral mucositis, Dental caries, antacidity | Phase II | Cellceutix (53) |
| HB1345       | Synthetic lipopeptide | Lipoteichoic acid binding, presumably membrane disruptor | Skin infections, acne | Preclinical | Helix BioMedix (56) |
| AA-139       | Arenicin | Membrane disruptor | MDR CUTL, pneumonia | Preclinical | Adenium Biotech (57) |
| OG252 and OG716 | Lantibiotics | Possibly by inhibition of cell wall biosynthesis, pore formation | *Clostridium difficile* infection in enteritis | Pre-investigational new drug (pre-IND) | Oragenics (58) |
| NVB333       | Semisynthetic derivative of deoxyactagardine B (lantibiotic) | Inhibition of cell wall biosynthesis | Gram-positive caused infections | Drug candidate, preclinical | Cantab Anti-infectives (59) |
| NP213 (Novexatin) | Cyclic arginine-based heptamer | Membrane disruption | Antifungal, onychomycosis | Phase II | Novabiotics (81) |
| NP339 (Novamycin) | Poly-Arginine based cationic peptide | Membrane perturbation | Yeast, mould infections | Preclinical | Novabiotics (81) |
| P113         | Histatin 5 | Possible surface-active agents, induce ATP release, activity on mitochondria | Gengivitis, oral candidasis | Phase II | Pacgen (82) |
(VABP) or bronchiectasis [43,44]. In 2014, POL7080 received QIDP status for the treatment of VABP caused by *P. aeruginosa*. A recent phase I clinical trial (September 2016) has been approved to study the drug–drug interactions of POL7080 and amikacin [45].

### 4.2. Linear AMPs

In addition to cyclic analogs, several linear AMPs are at different stages of development (Figure 2) [29,38,46].

Pexiganan, a 22-amino acid magainin analog, active against a broad spectrum of gram-positive and gram-negative aerobic and anaerobic bacteria as well as fungi. In addition, it is active against several strains of resistant bacteria, including methicillin-resistant *S. aureus* (MRSA), vancomycin-resistant *Enterococcus* (VRE), producers of extended-spectrum beta-lactamases (ESBL), and several multidrug resistant bacteria. Pivotal phase III clinical trials were initiated for pexiganan (Locilex, pexiganan cream 0.8%; Dipexium Pharmaceuticals) for the treatment of mild infections of diabetic foot ulcers. However, in October 2016, the
manufacturer announced that top-line data from the OneStep Phase II trial of Locilex® did not meet establish the superiority of the drug (the primary clinical endpoint) versus vehicle plus standardized wound care. Thus, Locilex is now being tested for use in skin and cSSI, such as infected surgical wounds, infected burns, and infected decubitus ulcers (pressure sores) [47].

Omiganan (CLS001 or MBI-226), a cationic dodecapeptide derived from indolicin (isolated from bovine neutrophils), exhibits activity against gram-positive and gram-negative bacteria as well as fungi. It is currently in phase II clinical trials for the treatment of acne vulgaris atopic dermatitis, genital warts, skin inflammation, and vulvar intraepithelial neoplasia. A phase III trial is underway testing omiganan for the topical treatment of the papules and pustules of rosacea, a chronic skin disease that affects over 14 million North Americans and 45 million people globally [48].

SGX942 (dusquetide), also derived from indolicin, is a fully synthetic, 5-amino peptide that acts as an innate defense regulator. Its safety and tolerability have been demonstrated in healthy volunteers (phase I clinical trial). It was granted Fast Track status from the FDA for the treatment of oral mucositis caused by radiation and/or chemotherapy treatment in head and neck cancer patients [49]. A phase II clinical study of this application was completed at the end of 2016. Preclinical data indicated that SGX94 is active in models of a wide range of therapeutic indications, including the severe side effects of chemotherapeutic agents and inflammation [50].

LTX-109 (Lytixar) is a short cationic peptidomimetic developed for topical treatments. Its fast-acting bactericidal mode of action is due to the selective and ultra-rapid disruption of microbial membranes. It is in phase I/II trial for the treatment of mild diabetic foot infections and nasal decolonization of S. aureus, including MRSA. Another phase II clinical trial is examining its use in the treatment of uncomplicated, gram-positive, skin infection and impetigo [51].

The Karolinska Institut, Karolinska Development AB (Sweden) and its portfolio company, Promore Pharma (former Pergamum AB), are the owners of three clinical-stage peptides (LL-37, PXL01 and DPK-060) developed for topical applications. These compounds are multifunctional, exhibiting broad antimicrobial activity but also modulating inflammation, immune functions, and wound-healing properties. They are thus intended for the treatment of chronic wounds, the prevention of scarring and adhesions, and, as antimicrobial agents. LL-37 (hCAP-18, derived from human cathelicidin) is being tested in a phase II clinical trial for the treatment venous leg ulcers. The results obtained thus far indicate a significantly improved healing rate compared to placebo. Its enantiomer (D-LL-37) also shows broad-spectrum antibacterial activity, suggesting an unspecific mode of action of these compounds. A phase II clinical trial examining the use of PXL-01 in the prevention of postsurgical adhesions yielded a positive outcome and a phase III clinical trial has been started. A statistically significant improvement was also reported in a phase II clinical trial of DPK-060 in outer ear infections [52].

Brilacidin is an arylamide foldamer peptidomimetic small molecule synthetically derived from human defensins. It shows high antibiotic activity against both gram-positive and gram-negative bacteria. A clinical phase IIb study comparing brilacidin to daptomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) yielded excellent positive results. Brilacidin received QIDP designation in 2012. In January 2016, Cellexutix announced a pivotal phase III trial of brilacidin for the treatment of ABSSSI infections caused by gram-positive bacteria [53].
The AMP C16G2 was designed to specifically target *Streptococcus mutans*, the acid-producing bacterium associated with dental caries and tooth decay. The peptide contains two functional regions: an *S. mutans*-selective targeting region and a broad-spectrum antimicrobial peptide (G2). Although it is bactericidal, via a membrane disruption mechanism similar to that of other AMPs, it does not affect other species in the oral biofilm. The target indication for C16G2 is the prevention of dental caries and related diseases of the oral cavity caused by microbial dysbiosis. C16G2 (administered as a dental gel) successfully completed a phase II clinical trial as an anticavity drug [54,55].

HB1345 (Helix Biomedix) is a synthetic lipohexapeptide with potent and broad spectrum antimicrobial activity when applied topically to skin infections. Its minimum inhibitory concentration (MIC) values against key pathogens, including *Propionibacterium acnes*, are in the 1–2 µg/ml range. HB1345 is in the preclinical phase for the treatment of acne, the lead indication chosen for this compound, based on its binding of lipoteichoic acid, involved in the inflammation that develops in acne. Similarly, HB1275 is a lipohexapeptide (no sequence disclosed) in the preclinical stage of development based on its potent antifungal activity against yeast and filamentous fungi, particularly *Trichophyton* (athlete’s foot, tinea capitis, and onychomycosis) [56].

Arenicin-3 is a 21-residue amphipathic β-hairpin peptide that contains two disulfide bridges. Isolated from the marine lugworm Arenicola marina, it binds to and disrupts the integrity of the outer and cytoplasmic membranes of gram-negative bacteria. The arenicin-3 analog AA139 is highly active against gram-negative ESKAPE pathogens, including multidrug resistant strains, and is currently in preclinical development. Among the possible applications are the treatment of urinary tract infections caused by *E. coli* strains (currently being tested by Adenium Biotech) and of both hospital-acquired and ventilation-associated pneumonia [57].

### 4.3. Lantibiotics

Lantibiotics are a naturally occurring class of AMPs that contain lanthionine, a nonproteinogenic amino acid. These antimicrobials are produced by bacteria and include nisin, which is used as a food preservative (E324). However, lantibiotics are also in development to fight infections. The main difficulty their large-scale production, as standard fermentation methods typically result in only minute amounts. A few candidates are available, such as OG253 and OG716 (no structures disclosed). OG235, obtained from the Oragenics discovery platform, has shown efficacy in an animal model of *C. difficile* enteritis (nonclinical testing). In 2015, it was at the FDA’s pre-Investigational New Drug application stage. In August 2016, Oragenics announced positive results for OG716, a second-generation orally active lantibiotic obtained from its Mutacin 1140 (MU1140) platform. Promising in vivo efficacy was reported, including decreased relapse and the reduced production of *C. difficile* spores compared to a vancomycin positive control [58].

The lantibiotic NVB333 is a semi-synthetic derivative of the lantibiotic deoxyoctagardine that exerts its antimicrobial activity by inhibiting cell wall biosynthesis. NVB333 is under development for the systemic treatment of gram-positive infections, including those caused by MRSA. It has also been proven to be active against strains resistant to currently available antibiotics, such as vancomycin, daptomycin, and linezolid. In vivo tests have shown high activity in murine models of thigh and lung infections and promising preliminary toxicology results [59].

### 5. Synergisms among AMPs

Due to their mechanism of action, in which the primary target is the bacterial membrane, AMPs are often effective against multiresistant bacteria. They are therefore excellent molecules to be combined with other antimicrobials to achieve more effective synergistic effects. For example, AMPs can be combined with antibiotics of low bacterial penetrability or when the mechanism of resistance involves the membrane.

A study of the use of colistin in combination with an antibiotic allowed both a reduction of the effective dose of colistin and the increased activity of the combined antimicrobials. Moreover, synergies of colistin with different antibiotics have been described, including quinolones fosfomycin, and aminoglycosides [60].

Other unusual combinations of antimicrobials have been tested, some with promising results. For example, linezolid and glycopeptides are antimicrobials used in to treat infections caused by gram-positive bacteria (gram-negatives are intrinsically resistant to these antimicrobials). Synergism between colistin and linezolid was demonstrated in vitro against *A. baumannii* clinical strains [61]. Colistin combined with glycopeptides was synergistic in vitro and in a *Galleria mellonella* model [62].

Among the most studied AMP synergies are colistin-carbapenem (β-lactams) [63,64] and, especially, AMPs with imipenem. The main mechanism of resistance to imipenem is a decrease in bacterial membrane permeability due to the lack of OprD, a porin used by imipenem to penetrate the outer membrane. The combination of imipenem with AMP could restore the ability of the former to penetrate the bacterial cell and thus bacterial susceptibility [37,65]. Rudilla et al. demonstrated the synergy between colistin-derived AMP38 and carbapenems in imipenem-resistant strains of *P. aeruginosa* [37]. In general, synergy has been observed with many polymyxin analogs. Particularly good results have been obtained in their potentiation of the activity of large hydrophobic antibiotics, such as the macrolides azithromycin and erythromycin [26].

The in vitro synergistic antibacterial activity of six proline-based cyclic dipeptides of natural origin [cyclo(D-Pro-L-Leu), cyclo(L-Pro-L-Met), cyclo(D-Pro-L-Phe), cyclo(L-Pro-L-Phe), cyclo(L-Pro-L-Tyr), and cyclo(L-Pro-D-Tyr)] with β-lactam antibiotics was reported by Kumar et al. [66] A synergistic effect of antibiotics with several newly developed short AMPs was described by Wang et al., who examined the combined activity of PMAP-36 and PRW4 with aminoglycosides [67].

The magainin analog pexiganan MSI-78 is a 22-amino acid amphipathic peptide that showed synergy in combination with β-lactam antibiotics [68], suggesting its use against infections caused by *P. aeruginosa*, *E. coli*, *S. aureus*, and *S. epidermidis*. 
The short AMP iseganan IB-367 (17-amino acid peptide) contains an amidated C-terminus and two disulfide bridges (Cys5–Cys14 and Cys7–Cys12). Synergies between IB-367 and the cyclic AMP colistin in \( P. \) \( \text{aeruginosa} \), \( E. \) \( \text{coli} \), \( A. \) \( \text{baumannii} \), and \( K. \) \( \text{pneumoniae} \) were demonstrated in an \textit{in vitro} checkerboard assay [69].

Nisin and its derivatives, nisin V (M21V) and nisin I4V, are lantibiotics with potent antibacterial activity against many gram-positive bacteria. Analysis by kill curves established that nisin V + penicillin or nisin I4V + chloramphenicol had enhanced inhibitory effects against \( S. \) \( \text{aureus} \) and \( S. \) \( \text{pseudintermedius} \), respectively, compared to the equivalent nisin A or when each antimicrobial was administered alone. These peptides have been used mainly in food microbiology [70].

The synergy of AMPs with \( \beta \)-lactam inhibitors recommends the further investigation of these and other such combinations to enhance the activity of ‘classical’ antimicrobial agents whose efficacy when used alone has been compromised by the emergence of resistant strains.

6. AMPs and biofilms

Most pathogens have the ability to form stable biofilms, which are a common cause of both persistent and device-associated infections. Because bacteria in biofilms are much less sensitive to antimicrobial agents than planktonic microbes the treatment of biofilm-type infections often fails. However, most AMPs are active against both planktonic and biofilm-forming bacteria, as demonstrated for KT2 and RT2, the semisynthetic peptide S8056, peptide 1018, and others. Other AMPs, such as LL-37, possess weak planktonic activity but show strong activity against biofilms [37,71]. Moreover, in addition to their ability to penetrate bacterial biofilms many AMPs prevent biofilm formation [18].

AMPs also enhance the activity of other antimicrobial agents when they are used in combination to treat infections involving biofilms. The broad-spectrum of activity shown by anti-biofilm AMPs includes interference with second messenger molecules and therefore signaling pathways, in both gram-positive and gram-negative bacteria [71].

However, several mechanisms of AMP resistance exhibited by biofilm bacteria have been described and threaten the effective use of these molecules. For instance, different bacterial subpopulations in the biofilm may differ in their motility or metabolism and thus be more resistant than others to AMPs. The development of resistance is also favored by the higher mutation rate of bacteria in biofilm communities than growing planktonically. The upregulation of efflux pumps or operon genes in biofilms (e.g. the \( \text{pmr} \) operon of \( P. \) \( \text{aeruginosa} \)) can also lead to high levels of AMP resistance [72,73]. The ability of the biofilm itself to reduce the diffusion of large AMPs (periplasmic glucan in \( P. \) \( \text{aeruginosa} \) biofilms) has also been demonstrated, but whether the diffusion rates of all types of AMPs are affected remains to be determined [73].

Despite these possible mechanisms of biofilm resistance, AMPs represent a novel and promising approach for the eradication of gram-positive and gram-negative bacteria in biofilms, which are mainly a feature of chronic and long-term infections. Additional work is needed to better understand the downstream processes of antibiofilm AMPs to allow the optimization of these drugs, when used either alone or in combination with other antimicrobial agents [71].

7. Anti-mycobacterial peptides

No novel drugs against \( M. \) \( \text{tuberculosis} \) sp. have been introduced for clinical use in the past 40 years. AMPs offer a new approach and most of those investigated thus far for their efficacy against \( M. \) \( \text{tuberculosis} \) spp. are either natural peptides or derived from natural peptides [74,75]. Several examples are provided in the following:

Defensins such as HNP1-4 are human neutrophil peptides active on skin or other epithelial surfaces, usually in the presence of low concentrations of salt. HNPs kill mycobacteria probably by inhibiting the biosynthesis of macromolecules and/or increasing the permeability of the bacterial cell membrane [74].

Lactoferrins are iron-binding proteins belonging to the transferrin family of proteins. Silva et al. [76] studied the activity of human and bovine lactoferrins, including hLFcin1-11, LFcin17-30, and other variants obtained by specific amino acid substitutions, reporting promising results with some of these peptides.

Cathelicidin or its terminal region (LL-37), an AMP already mentioned in this review, shows moderate activity against \( M. \) \( \text{tuberculosis} \) \( \text{H37Rv} \) strains as well as \( M. \) \( \text{tuberculosis} \) \( \text{H37Rv} \) multidrug resistant strains, Its MIC is between 2 and 10 \( \mu \)g/ml. Rivas-Santiago et al. also showed the activity of three LL37-related peptides: E2, E6, and CP26 [77].

Several synthetic peptides with antimycobacterial activity have been developed, including D-LAK peptides, which are linear, cationic, amphipathic \( \alpha \)-helix-shaped AMPs [78] that at low concentrations have extracellular antimycobacterial activity; however, despite mild cytotoxicity against THP-1 cells they failed in completely eradicating intracellular mycobacteria.

A library of small (~10 amino acids) synthetic AMPs, has been tested and some of the peptides exhibit interesting activities against \( M. \) \( \text{tuberculosis} \) and \( M. \) \( \text{smegmatis} \). Their MIC values were as low as 1.1 \( \mu \)M and cytotoxicity against THP-1 cells was low [79].

8. Antifungal peptides

Echinocandins are antifungal peptides that show fungicidal activity against \( \text{Candida} \) spp. and fungistatic activity against \( \text{Aspergillus} \) spp. [80] Many have been approved by the FDA and EMEA (European Medicine Agency) Caspofungin (Merck), Anidulafungin (Pfizer), and Micafungin (Astellas) have been available since the early 2000s and are widely used for the treatment of systemic candidemia and candidiasis. All of them are cyclic hexapeptides linked with a fatty acid chain (semisynthetic peptides) and were derived from pneumocandins (natural lipopeptides).

NP213 is a cyclic arginine-based heptamer (Table 2) with fungicidal activity. As the active ingredient of Novexatin®, it has been formulated as a brush-on-treatment for fungal nail infections (onychomycosis). Phase I and Ila clinical studies
demonstrated that NP213 is safe, well-tolerated, and effective. Novabiotics is also developing Novamycin (NP339), a novel antifungal peptide for the treatment of aspergillosis, candidiasis, and cryptococcosis, as well as Novarifyn (NP432), an antibiotic peptide to treat infections by pathogens such as MRSA, *P. aeruginosa*, *C. difficile*, *A. baumannii*, and *E. coli*. Both are expected to undergo initial clinical studies in 2017 [81].

P113 (Table 2) is a 12-amino-acid cationic and amphipathic AMP derived from naturally occurring histatin 5, an oral defense protein found in saliva. Clinical phase I and II results showed that P113 is safe and effective in the treatment of gingivitis and oral candidiasis. In addition, nonprescription over-the-counter products containing P113, including a mouthwash, oral spray, and antibacterial hand cream, have recently become available [82].

Qi et al. [83] described a series of short (9–11 amino acids) linear peptide with an α-helical structure. Some (P11-5, P11-6, and P9-4) have shown promising activity against the yeast *Candida albicans* (MIC = 3.1 µg/ml) and against the filamentous fungi *Fusarium solani* (MICs = 12.5–50 µg/ml). Importantly, both of these antifungal peptides are of low toxicity.

9. Antiparasitic peptides

The diversity of parasitic groups, with their complex life cycles that typically involve multiple stages in different hosts and their enormously different protein expression and membrane composition, have hindered the rapid development of AMPs for the treatment of parasitic disease [84].

Nevertheless, a broad range of AMPs (both naturally occurring peptides and their structural analogs) has been shown to be effective against a variety of parasitic infections caused by protozoa (Chagas disease, human African trypanosomiasis, malaria, and leishmaniosis), and helminths (taeniasis and onchocerciasis). Moreover, some of these microbes, for example the filarial worm *Onchocerca volvulus*, may be a source of novel AMPs with therapeutic potential against microbial infections [85].

A few examples of AMPs effective against parasitic diseases are provided in the following.

9.1. *Plasmodium*

Magainin-2 was one of the first antiprotozoal host defense peptide to be identified: Its antiplasmodium activity was described over 35 years ago [86]. The inhibition of *Plasmodium falciparum* growth by the hybrid peptide cepacin-melittin (CA 1–13 and H 1–13) has also been reported [87].

Other antimalarial peptides produced by insects are defensins (drosomycins), gambicins, and gomesins. Dermaseptins, of amphibian origin, are highly active against *P. falciparum*. A high level of antiplasmodial activity has been demonstrated for the acyl-derivative desmaseptin K4-S4 [88].

Scorpion, a peptide isolated from spider’s venom, also has inhibitory activity against *P. falciparum* parasitemia, as do the synthetic antimalarial AMPs NK-2, D-HALO-rev, and IDR-1018. Some antimalarial peptides act selectively on infected erythrocytes, leaving the membranes of healthy cells undisturbed and are thus of particular interest as antimalarial drugs [89]. Their development is highly anticipated because artemisinin-resistance is becoming increasingly frequent, especially in Asia [90].

9.2. *Trypanosoma brucei*

AMPs have a clear established role in the immunity of the African trypanosomiasis vector (tsetse fly). For example, attacin, defensin, and cepacin participate in the insect’s innate immunity. Conversely, several trypanocidal peptides from mammalian hosts have also been described, including the α- and β-defensins and cathelicidins (sheep SMAP-29 and pig protegrin-1). All of them show in vitro trypanolytic activity against both procyclic and bloodstream forms of *Trypanosoma brucei* [91]. Peptide antibiotics isolated from fungi (leucinostatin A and B, alamethicin and tushimycin) also exhibit trypanolytic activity both in vitro and in vivo, although in some cases with a high oral toxicity.

Among the synthetic AMPs targeting *T. brucei* are the cell penetrating peptide transportan TP10, a derivate of bovine BMP-27, and small synthetic peptides derived from insect defensins. In addition, unconventional AMPs, such as neutropetides, trypanosome lytic factor, and small hydrophobic peptides (SHP-1 and SHP-2), kill African trypanosomes mainly by increasing the rigidity of their membranes [92].

9.3. *Trypanosoma cruzi*

Three classes of antitrypanosomal peptides from insect sources have been extensively studied: apidecins, cecropins, and melittins. Cecropin and melittin, used as a hybrid in the treatment of malaria, have been combined with magainin 2 as an antitrypanocidal agent with activity 10-fold higher than when used alone. The synthetic cecropins SB-37 and Shiva-1 are 10 times more effective than natural cecropins in damaging and killing the parasite.

Temporin peptides, the smallest amphipathic α-helical containing AMPs found in nature, are produced by frogs, which like other amphibians are naturally resistant to *Trypanosoma cruzi* infection. Temporin-SHd has significant inhibitory effect against trypanosomes but its toxicity to human cells has discouraged its use. Temporizin-1 is an artificial hybrid peptide containing pore-forming gramicidin but with a reduction in the region that inserts into membranes. Its moderate toxicity toward mammalian cells and improved antitrypanosomal activity recommend its further development as a novel antitrypanosomal drugs [93].

9.4. *Leishmania*

Leishmanicidal peptides include temporins, bombins, magainins, and cathelicidins [94]. Dermaseptin S4 and its synthetic analogs potently induce the lysis of promastigotes. Anti-*Leishmania* activity has been demonstrated for the AMPs gomesin, indolicin, and thionins, isolated from different organisms. Pexiganan a synthetic magainin-based lysine-rich peptide, originally tested in a phase III clinical trial for diabetic foot ulcers but was also found to induce apoptosis in leishmanial promastigotes.
and the intracellular parasites *CRIPTOSPORIDIUM PARVUM* and *C. HOMINIS* can also be killed by AMPs/HDPs.

Peptide drugs for protozoan diseases are still in the early stages of testing, but the available evidence suggests that they will be effective in the treatment of malaria and other diseases. However, the continued development of AMPs for use in the treatment of *Plasmodium* or leishmanial infections depends on several factors, including a reduction of the high production costs, and an improvement of the stability of the drugs, and a reduction of the required dose, to avoid toxicity [95]. A promising strategy is the use of nanotechnologies and peptide encapsulation to increase the selectivity and half-life of the drug.

9.5. *Taenia* and cysticercosis

Temporin A and iseganan IB-367 (a protegrin-1 derivative of the cathelicidins family) have antiparasitic effects against *Taenia crassiceps*, the causative agent of tapeworm. In *in vitro* tests, both drugs damage the tegumentary surface of the cysticerci to induce morphological changes [96].

9.6. *Onchocerca volvulus*

Extracts of *O. volvulus* obtained from infected patients were shown to also contain a human neutrophil peptide 1–3 (HNP 1–3), a defensin that mediates the macrophage response to microorganisms. HNP 1–3 binds to the surface of *O. volvulus*, which is not affected by the peptide. Others excretory/secretory products of *Onchocerca* were found to have significant antibacterial activity against *Escherichia coli*

Helmintic defense molecules (HDMs) are a novel family of molecules secreted by helmintic parasites and exhibiting structural and biochemical characteristics similar to those of mammalian helminth defense peptides (HDPs) [97]. A comparison of four trematode cathelicidin-like HDMs derived from *Schistosoma mansoni* and *Fasciola hepatica* showed that unlike HDPs, they exhibit no antimicrobial activity and are noncytotoxic to mammalian cells (macrophages and red blood cells). However, both HDPs and HDMs suppress the activation of macrophages by microbial stimuli and alter the response of B cells to cytokine stimulation. These observations suggest that HDMs are a novel family of HDPs that evolved to regulate the immune responses of their mammalian hosts, by retaining potent immune modulatory properties without causing deleterious cytotoxic effects. This strategy allows helminths to modulate host immune responses in establishing an environment that facilitates the reproduction and survival of the parasite [98]. A phylogenetic analysis revealed that HDMs are conserved across the majority of trematode species, including liver flukes and blood flukes.

In summary, HDMs hold promise as a more attractive therapeutic option than HDPs, as they show all the potent immunomodulatory effects of the latter without their cytotoxic and cytolitic effects.

10. Conclusion

Given the ubiquity of AMPs in nature and their production by almost all living organism, these peptides and their synthetic derivatives have become an interesting alternative to traditional antibiotics. This has been well-demonstrated by the renewed use of colistin as a first-line antimicrobial to treat severe infections caused by multidrug-resistant microorganisms. Moreover, the AMP pipeline currently includes over 20 different compounds in all clinical stages of development.

The importance of AMPs lies in their multiple mechanisms of action to produce a killing effect. This may prevent the development of bacterial resistance, which generally relies on more than a single mutational or adaptive event. Furthermore, the ability of AMPs to disrupt the bacterial membrane and thus alter its permeability makes them interesting compounds for use in synergistic combinations with other antimicrobial agents.

11. Expert opinion

Antimicrobial peptides, also called host defense peptides (HDPs), were first discovered on the external surface of amphibians, in studies of why their nutritive and humid surface was not permanently infected. Since then these small molecules have been shown to form part of the innate immune response of almost (if not all) classes of life [99]. For instance, the polymorphonuclear neutrophil and natural killer cells of vertebrates produce AMPs active against microbes (including protozoa, fungi, and bacteria) and even tumor cells. Among bacteria, the genus *Bacillus* produces several AMPs of interest in human medicine, such as tyrothricin, gramicidin D, polymyxin B, and colistin. Indeed, the widely used antibiotic bacitracin is a mixture of bacterial AMPs. Among the other bacterial species that produce AMPs is *Lactobacillus*, whose peptides are extensively used in the food industry, including as L-antibiotics (nisin, lactacin, etc.) [70]. Also of interest are microcins, a family of plasmid-encoded AMPs secreted by Enterobacteria [100]. Fungal AMPs include the peptaibol family of peptides, which contain unusual amino acids. AMPs are also produced by plants and participate in plant defense (defensins) responses. Within the animal kingdom, AMP production is almost universal, with humoral defense peptides described in sponges, cnidarians, and mollusks. In these invertebrates living in marine and freshwater environments, AMPs are a fundamental strategy guaranteeing their survival. Among the AMPs produced by arthropods are the positive charged cecropins, thanatin, melitin, apidaecins, and ceratotoxins. The defense strategies of fish also rely on AMPs [99], as demonstrated by cathelicidins and β-defensins, piscidins, and hepcidins, whose chemical structures and mechanisms of action are highly diverse. Amphibians produce many AMPs, including bombinins, cathelicidins, and dermaseptin, whose mechanisms of action are highly diverse. Reptiles and birds, like other vertebrates, also produce AMPs belonging to the cathelicidin and defensin families. Besides AMPs belonging to the cathelicidin and defensin families, non-human mammals produce other well-characterized AMPs, such as platelet antimicrobial proteins (PMPs), dermcidin, and hepcidins [99]. It remains unclear to what extent these AMPs play a central role in the highly evolved immune response of mammals, although, in some cases, such as LL-37 an...
amphipathic molecule that acquires an α-helical structure when interacting with cell membranes to form transmembrane pores, their role has been very well recognized.

An appreciation of the diversity of AMPs in nature has stimulated the development of synthetic derivatives in the laboratory. They are gaining increasing importance given the dramatic rise in resistant bacteria [36], although both their antimicrobial action and cellular toxicity must be well-defined. Nonetheless, given the scarcity of new natural antimicrobials, synthetic AMPs are sure to be a promising path with which to improve the therapeutic arsenal against infectious diseases.

Acknowledgments

We thank Dr Wendy Ran for editing the manuscript.

Funding

All the authors are supported by the University of Barcelona. F Rabanal is also supported by the Fundació Bosch i Gimpera, Xarxa de Referència en Biotecnologia (XRB, Generalitat de Catalunya) and the European Institute of Innovation and Technology (EIT Health).

Declaration of interest

F Rabanal and M Viñas are members of the ENABLE (European Gram-Negative Antibacterial Engine) European consortium (IMI-ND4BB). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

References

Papers of special note have been highlighted as either of interest (+) or of considerable interest (++), and are referred to in the context of the subject matter or materials discussed in the manuscript apart from those disclosed.

1. Van Epps HL. René Dubos: unearthing antibiotics. J Exp Med. 2006;203:259.
2. Davies J. Where have all the antibiotics gone? can. J Infect Dis Med Microbiol. 2006;17:287–290.
3. Ruiz-Martínez L, López-Jiménez L, d’Ostuni V, et al. A mechanism of carbapenem resistance due to a new insertion element (ISPa133) in Pseudomonas aeruginosa. Int Microbiol. 2011;14:51–58.
4. Madec J-Y, Haenni M, Nordmann P, et al. ESBL/AmpC- and carba-
penemase-producing Enterobacteriaceae in animals: a threat for humans? Clin Microbiol Infect. 2017 28 Jan 2017. DOI:10.1016/j.
cmi.2017.01.013.
5. Li Y, Metcalfe BJ, Chochoa S, et al. Penicillin-binding protein trans-
destate signatures for tracking and predicting β-lactam resistance
level in Streptococcus pneumoniae. MBio. 2016;7:e00756–16.
6. Mendelman PM, Caugant DA, Kalaitzoglou G, et al. Genetic diversity
of penicillin G-resistant Neisseria meningitidis from Spain. Infect
Immun. 1989;57:1025–1029.
7. Nikaido H, Pagès J-M. Broad-spectrum efflux pumps and their role
in multidrug resistance of Gram-negative bacteria. FEMS Microbiol
Rev. 2012;36:340–363.
8. Algbru A, Comito N, Kashtanov D, et al. Control of biofilm forma-
tion: antibiotics and beyond. Appl Environ Microbiol. 2017;83:
e02508–16.
9. Enright MC, Robinson DA, Randle G, et al. The evolutionary history
of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl
Acad Sci U S A. 2002;99:7687–7692.
10. Springer B, Kidan YG, Pramananathan T, et al. Mechanisms of strep-
tomycin resistance: selection of mutations in the 16S rRNA gene
conferring resistance. Antimicrob Agents Chemother. 2001;45:2877–2884.
11. Humphries RM, Pollett S, Sakoulas G. A current perspective
on daptomycin for the clinical microbiologist. Clin Microbiol Rev.
2013;26:759–780.
12. O’Neil J. Tackling drug-resistant infections globally: final report
and recommendations. Available from: https://amr-review.org/sites/
default/files/160525_Final_paper_with_cover.pdf. [Last accessed 5
Dec 2016].
13. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no
ESKAPE! An update from the infectious diseases society of America.
Clin Infect Dis. 2009;48:1–12.
14. EDCD, antimicrobial-resistance-europe-2014. Available from:
http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resis-
tance-europe-2014.pdf. [cited 2016 Nov]
15. Davies J, Davies D. Origins and evolution of antibiotic resistance. 
Microbiol Mol Biol Rev. 2010;74:417–433.
16. Jeness H, Hamill P, Hancock REW. Peptide antimicrobial agents. 
Clin Microbiol Rev. 2006;19:491–511.
17. Karaikos I, Souli M, Galani I, et al. Colistin: still a lifesaver for
the 21st century? expert opin. Drug Metab Toxicol. 2016;13:1–13.
18. Rios AC, Moutinho CG, Pinto FC, et al. Alternatives to overcoming
bacterial resistances: state-of-the-art. Microbiol Res. 2016;191:51–80.
19. Kozlowska J, Vermeer LS, Rogers GB, et al. Combined systems
approach reveals highly plastic responses to antimicrobial peptide
challenge in Escherichia coli. Plos Pathog. 2014;10:e1004104.
20. Brogden KA. Antimicrobial peptides: pore formers or metabolic
inhibitors in bacteria? Nat. Rev Microbiol. 2005;3:238–250.
21. A broad overview describing the resistance strategies that
microorganisms use to circumvent antimicrobial killing and
the different mechanisms of antimicrobial-peptide-induced
pore formation.
22. Epand RF, Ramamoorthy A, Epand RM. Membrane lipid composi-
tion and the interaction of pardaxin: the role of cholesterol. Protein
Pept Lett. 2006;13:1–5.
23. Hallock KJ, Lee D-K, Ramamoorthy A. MSI-78, an analogue of the
magainin antimicrobial peptides, disrupts lipid bilayer structure via
a surface curvature strain. Biophys J. 2003;84:3052–3060.
24. Katherine A, Henzler-Wildman F, Gary V, et al. Perturbation of the
hydrophobic core of lipid bilayers by the human antimicrobial
peptide LL-37. Biochemistry. 2004;43:8459–8469.
25. Teixeira V, Feijo MJ, Bastos M. Role of lipids in the interaction
of antimicrobial peptides with membranes. Prog Lipid Res. 2012;51:149–177.
26. A detailed description of the role of the composition of lipids in
the antimicrobial peptides activity and bacterial membrane
permeabilization.
27. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action
and resistance. Pharmacol Rev. 2003;55:27–55.
28. Hassan M, Kjos M, Nes IF, et al. Natural antimicrobial peptides from
tacteria: characteristics and potential applications to fight against
antibiotic resistance. J Appl Microbiol. 2012;113:723–736.
29. Nguyen LT, Haney EF, Vogel HJ. The expanding scope of antimi-
crobial bacteria: characteristics and potential applications to fight against
antimicrobial resistances: state-of-the-art. Expert Opin. Drug Metab
Toxicol. 2012;8:511–524.
30. Gruenheid S, Moual H. Resistance to antimicrobial peptides in
Gram-negative bacteria. FEMS Microbiol Lett. 2012;330:81–92.
31. This study describes the most relevant mechanisms by which
gram-negative pathogens resist AMPs. Among them, AMPs can
be inactivated by bacterial and host proteases; LPS modifica-
tions and presence of capsule can prevent the interaction of
AMP with bacterial membrane; AMPs can be pumped in or out
of bacteria by efflux pumps and AMPs can suppress their
expression by host cells.
29. Francesc R, Cajal Y. Therapeutic potential of antimicrobial peptide. In: Villa TG, Vinas M, editors. New weapons to control bact. Growth Ed: Springer International Publishing; 2016.
30. Tang X-J, Thibault P, Boyd RK. Characterisation of the tyrocidine and gramicidin fractions of the tyrothricin complex from Bacillus brevis using liquid chromatography and mass spectrometry. Int J Mass Spectrom Ion Process. 1992;122:133–179.
31. Tyrothricin - Drugs.comAvailable from: https://www.drugs.com/international/tyrothricin.html. [Last accessed 13 Nov 2016].
32. Stevenson CL. Advances in peptide pharmaceuticals. Curr Pharm Biotechnol. 2009;10:122–137.
33. Boucher HW, Talbot GH, Benjamin DK, et al. 10 x '20 progress—development of new drugs active against gram-negative bacilli: an update from the infectious diseases society of America. Clin Infect Dis. 2013;56:1685–1694.
34. Pastor M, Moreno-Sastre M, Esquisabel A, et al. Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis. Int J Pharm. 2014;477:485–494.
35. Sans-Serramitjana E, Fusté E, Martínez-Garriga B, et al. Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients. J Cyst Fibros. 2016;15:611–618.
36. Rabanal F, Grau-Campistany A, Vila-Farrés X, et al. A bioinspired peptide scaffold with high antibiotic activity and low in vivo toxicity. Sci Rep. 2015;5:10558.
» New design of polymyxin analogs modifying not only the amino acid sequence but also introducing disulfide bonds within the peptide scaffold to reduce toxicity and facilitate metabolization upon accumulation in renal cells, the suspected cause of nephrotoxicity.
37. Rudilla H, Fusté E, Cajal Y, et al. Synergistic antipseudomonal effects of synthetic peptide AMP38 and carbapenems. Molecules. 2016;21:1223.
38. Grau-Campistany A, Pujol M, Marqués AM, et al. Membrane interaction of a new synthetic antimicrobial lipopeptide sp-85 with broad spectrum activity. Colloids Surfaces Physicochem Eng Asp. 2015;480:307–317.
39. Grau-Campistany A, Manresa A, Pujol M, et al. Tryptophan-containing lipopeptide antibiotics derived from polymyxin B with activity against Gram positive and Gram negative bacteria. Biochim Biophys Acta. 2016;1858:333–343.
40. Bacitracin. Available from: http://www.drugbank.ca/drugs/DB00662. [Last accessed 8 Nov 2016].
41. CUBICIN® webpage. Available from: http://cubicin.com/. [Last accessed 5 Nov 2016].
42. Knight-Connoni V, Maccio C, Chesnel L, et al. Discovery and development of surotomycin for the treatment of Clostridium difficile. J Ind Microbiol Biotechnol. 2016;43:195–204.
43. Srinivas N, Jetter P, Ueberbacher BJ, et al. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science. 2010;327:1010–1013.
44. Polyphor - POL7080. Available from: http://www.polyphor.com/products/pol7080. [Last accessed 13 Nov 2016].
45. Polyphor- Ltd POL7080 - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02897869. [Last accessed 13 Nov 2016].
46. Afacan NJ, Yeung ATY, Pena OM, et al. Therapeutic potential of host defense peptides in antibiotic-resistant infections. Curr Pharm Des. 2012;18:807–819.
47. Dipexium Pharmaceuticals (DPRX) [Internet]. [cited 2016 Nov 13]. Available from: http://www.dipexiumpharmaceuticals.com/locilux/overview.
48. Cutanea Life Sciences. Available from: http://www.cutanea.com/. [Last accessed 13 Nov 2016].
49. Soligenix- SGX942- Oral Mucositis. Available from: http://www.soligenix.com/pipeline/biotherapeutics/sgx942-oral-mucositis/. [Last accessed 13 Nov 2016].
50. Kudrimoti M, Curtis A, Azawi S, et al. Duquesquete: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotechnol. 2016;239:115–125.
51. Lytix Biopharma - Itx109. Available from: http://www.lytixbiopharma.com/antibacterials/itx109/. [Last accessed 5 Nov 2016].
52. Karolinska Development. ‘LL-37. Available from: http://www.karolinskadevelopment.com/en/porfolio/infections-and-wound-healing/ll-37/. [Last accessed 13 Nov 2016].
53. Cellceutix Corporation - Brilacidin. Available from: http://cellceutix.com/brilacidin/#hash.HimRvENG.dpbs. [Last accessed 22 Nov 2016].
54. C3 Jian. Available from: http://www.c3-jian.com/c3-jian-completes-second-phase-2-clinical-trial-of-anti-cavity-drug/. [Last accessed 5 Nov 2016].
55. Guo L, McLean JS, Yang Y, et al. Precision-guided antimicrobial peptide as a targeted modulator of human microbial ecology. Proc Natl Acad Sci U S A. 2015;112:7569–7574.
• This study demonstrates the use of C16G2 (a targeted AMP that kills cariogenic pathogen Streptococcus mutans) to modulate the microbiome structure allowing insights into the key community role of specific bacterial species and also indicates the therapeutic potential of C16G2 to achieve a healthy oral microbiome.
56. Helix BioMedix | Anti-Infective HB1345 Available from: http://www.helixbiomedix.com/antinfective.html. [Last accessed 13 Nov 2016].
57. Adenum Biotech. Available from: http://adeniumbiotech.com/pipeline/. [Last accessed 5 Nov 2016].
58. Oragenics, Inc. (OGEN),OG253. Available from: http://www.oraigenics.com/technology-pipeline/antibiotics/og253. [Last accessed 13 Nov 2016].
59. Cantab Anti-infectives - Products Overview. Available from: http://www.cantabanti.com/nvb333.html. [Last accessed 6 Nov 2016].
60. Ni W, Shao X, Di X, et al. In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis. Int J Antimicrob Agents. 2015;45:8–18.
• This meta-analysed studied 70 articles and 31 conference proceedings reporting testing of polymyxin in combination with 11 classes consisting of 28 antibiotic types against 1484 A. baumannii strains
61. Liu B, Liu Y, Di X, et al. Colistin and anti-Gram-positive bacterial agents against Acinetobacter baumannii. Rev Soc Bras Med Trop. 2014;47:451–456.
62. Hornsey M, Wareham DW. In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2011;55:3534–3537.
63. Yang H, Chen G, Hu L, et al. Enhanced efficacy of imipenem-colistin combination therapy against multiple-drug-resistant Enterobacter cloacae in vitro activity and a Galleria mellonella model. J Microbiol Immunol Infect. 2016;29 Jan 2016. DOI:10.1016/j.jmii.2016.01.003.
64. D'Souza BB, Padmaraj SR, Rehka PD, et al. In vitro synergistic activity of colistin and cetazidime or ciprofloxacin against multidrug-resistant clinical strains of Pseudomonas aeruginosa. Microb Drug Resist. 2014;20:550–554.
65. Leu H-S, Ye -J-J, Lee M-H, et al. Synergy of imipenem/colistin methanesulfonate combinations against imipenem-nonsusceptible multidrug-resistant Acinetobacter baumannii. J Microbiol Immunol Infect. 2014;47:406–411.
66. Kumar SN, Lankalapalli RS, Kumar BSD. In vitro antibacterial screening of six proline-based cyclic dipeptides in combination with β-lactam antibiotics against medically important bacteria. Appl Biochem Biotechnol. 2014;173:116–128.
67. Wang Z, Zhang L, Wang J, et al. Synergistic interaction of PMAP-36 and PRW4 with aminoglycoside antibiotics and their antibacterial mechanism. World J Microbiol Biotechnol. 2014;30:3121–3128.
68. Giacometti A, Cirioni O, Kamysz W, et al. In vitro activity of MSI-78 alone and in combination with antibiotics against bacteria responsible for bloodstream infections in neutropenic patients. Int J Antimicrob Agents. 2005;26:235–240.
69. Simonetti O, Cirioni O, Ghiselli R, et al. In vitro activity and in vivo animal model efficacy of IB-367 alone and in combination with
imipenem and colistin against Gram-negative bacteria. Peptides. 2014;55:17–22.
70. Mulet-Powell N, Lacoste-Armynt AM, Víñas M, et al. Interactions between pairs of bacteriocins from lactic bacteria. J Food Prot 1998;61:1210–1212.
71. Pletcher D, Hancock REW. Antibiofilm peptides: potential as broad-spectrum agents. J Bacteriol. 2016;198:2572–2578.
72. Heiby N, Bjarndit E, Givskov M, et al. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010;35:322–332.
73. Nuri R, Shprung T, Shai Y. Defensive remodeling: how bacterial surface properties and biofilm formation promote resistance to antimicrobial peptides. Biochim Biophys Acta. 2015;1848:3089–3100
74. Padhi A, Sengupta M, Sengupta S, et al. Antimicrobial peptides and proteins in mycobacterial therapy: current status and future prospects. Tuberculosis. 2014;94:363–373.
75. Gutmann T. Interaction between antimicrobial peptides and mycobacteria. Biochim Biophys Acta. 2016;1858:1034–1043.
76. Silva T, Magalhães B, Maia S, et al. Killing of Mycobacterium avium by lactoferricin peptides: improved activity of arginine- and D-amino-acid-containing molecules. Antimicrob Agents Chemother. 2014;58:3461–3467.
77. Rivas-Santiago B, Rivas Santiago CE, Castañeda-Delgado JE, et al. Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis. Int J Antimicrob Agents. 2013;41:143–148.
78. Lan Y, Lam JT, Siu GKH, et al. Cationic amphipathic D-enantiomeric antimicrobial peptides with in vitro and in vivo activity against drug-resistant Mycobacterium tuberculosis. Tuberculosis. 2014;94:678–689.
79. Ramón-García S, Mikut R, Ng C, et al. Targeting Mycobacterium tuberculosis and other microbial pathogens using improved synthetic antibacterial peptides. Antimicrob Agents Chemother. 2013;57:2295–2303.
80. The activity of a library of synthetic short peptides were tested against mycobacterial strains. Some of them presented a good activity, being some of the synthetic peptides a potential alternative for the antimycobacterial treatment.
81. Rautenbach M, Troskie AM, Vosloo JA. Antifungal peptides: to be or not to be membrane active. Biochimie. 2016;130:132–145.
82. Novabiotics NP213. Available from: http://www.novabiotics.co.uk/pipeline/novexatin-np213. [Last accessed 13 Nov 2016]
83. Pacgen- Progress on PAC-113. Available from: http://www.marketed.com/press-release/pacgen-announces-progressive-on-pac-113-license-2151000.htm. [Last accessed 13 Nov 2016]
84. Qi X, Zhou C, Li P, et al. Novel short antibacterial and antifungal peptides with low cytotoxicity: efficacy and action mechanisms. Biochem Biophys Res Commun. 2010;398(3):594–600.
85. Angélique L, Frederik W, Garmi J, et al. The potential use of natural and structural analogues of antimicrobial peptides in the fight against neglected tropical diseases. Molecules. 2015;8:15392–15433.
86. Gwagw RW, Kaslow D, Lee JY, et al. Effects of magainins and cecropins on the sporogonic development of malaria parasites in mosquitoes. Infect Immun. 1989;57:2628–2633.
87. Boman HG, Wade D, Boman IA, et al. Antibacterial and antimalarial properties of peptides that are cecropin-mellitin hybrids. FEBS Lett. 1989;259:103–106.
88. Feder R, Neushtai R, Mor A. Affinity driven molecular transfer from erythrocyte membrane to target cells. Peptides. 2001;22:1683–1690.
89. Vale N, Aguiar L, Gomes P. Antimicrobial peptides: A new class of antimalarial drugs? Front. Pharmacol. 2014;5:275.
90. Zhou L-J, Xia J, Wei H-X, et al. Risk of drug resistance in Plasmodium falciparum malaria therapy—a systematic review and meta-analysis. Parasitol Res. 2017;116:781–788.
91. McGwire BS, Olson L, Tack BF, et al. Killing of African trypanosomes by antimicrobial peptides. J Infect Dis. 2003;188:146–152.
92. Harrington JM. Antimicrobial peptide killing of African trypanosomes. Parasite Immunol. 2011;33:461–469.
93. Souza ALA, Faria RX, Calabrese KS, et al. Temporizin and temporizin-1 peptides as novel candidates for eliminating Trypanosoma cruzi. Plos One. 2016;11:1–20.
94. Lacerda AF, Pelegrini PB, de Oliveira DM, et al. Anti-parasitic peptides from arthropods and their application in drug therapy. Front Microbiol. 2016;7:1–11.
95. Torrent M, Pulido D, Rivas L, et al. Antimicrobial peptide action on parasites. Curr Drug Targets. 2012;13:1138–1147.
96. Landa A, Jiménez L, Willms K, et al. Antimicrobial peptides (Temporin A and Iseganan IB-367): effect on the cysterci of Taenia crassiceps. Mol Biochem Parasitol. 2009;164:126–130.
97. Robinson MW, Donnelly S, Dalton JP. Helminth defence molecules-immunomodulators designed by parasites! Front. Microbiol. 2013;4:1–4.
98. Thivierge K, Cotton S, Schaefer DA, et al. Cathelicidin-like Helminth peptides from arthropods and their application in drug therapy. Front Microbiol. 2016;7:1–11.
99. Duquesne S, Destoumieux-Garzón D, Peduzzi J, et al. Microcins, gene-encoded antibacterial peptides from enterobacteria. Nat Prod Rep. 2007;24:708–734.